Refractory Erdheim-Chester disease

Drug	Drug Name	Drug Description
DB08881	Vemurafenib	Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]

Drug	Drug Name	Target	Type
DB08881	Vemurafenib	Serum albumin	carrier
DB08881	Vemurafenib	Alpha-1-acid glycoprotein 1	carrier
DB08881	Vemurafenib	Cytochrome P450 1A2	enzyme
DB08881	Vemurafenib	Cytochrome P450 2D6	enzyme
DB08881	Vemurafenib	Cytochrome P450 3A4	enzyme
DB08881	Vemurafenib	Serine/threonine-protein kinase B-raf	target
DB08881	Vemurafenib	Multidrug resistance-associated protein 1	transporter
DB08881	Vemurafenib	ATP-binding cassette sub-family G member 2	transporter
DB08881	Vemurafenib	Cytochrome P450 2C9	enzyme

Drug	Drug Name	Phase	Status	Count